scholarly journals Επίπεδα αδιπονεκτίνης στον ορό και τη βρογχοκυψελιδική έκπλυση (BAL) ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα (NSCLC)

2017 ◽  
Author(s):  
Παρασκευή Μπούρα
Keyword(s):  
Body Mass Index ◽  
Regression Analysis ◽  
Confidence Interval ◽  
Bronchoalveolar Lavage ◽  
Body Mass ◽  
Cox Regression ◽  
Performance Status ◽  
Hazard Ratio ◽  
Cox Regression Analysis

Η αδιπονεκτίνη είναι μια από τις κυριότερες αδιποκίνες που παράγονται από τον λιπώδη ιστό. Προηγούμενες μελέτες έδειξαν τη δυνητική χρησιμότητα της αδιπονεκτίνης ορού ως διαγνωστικού ή/και προγνωστικού βιοδείκτη σε διάφορους συμπαγείς όγκους, αλλά τα σχετικά δεδομένα για τον καρκίνο του πνεύμονα, ειδικότερα, είναι ελλιπή. Επιπρόσθετα, η διαγνωστική ή και προγνωστική αξία των επιπέδων αδιπονεκτίνης σε άλλα βιολογικά υγρά -εκτός του περιφερικού αίματος- ασθενών με καρκίνο πνεύμονα ή και με οποιαδήποτε άλλη μορφή καρκίνου, δεν έχει, απ’ όσο γνωρίζουμε, μελετηθεί. Ο πρωταρχικός σκοπός της παρούσας μελέτης ήταν η περαιτέρω διερεύνηση της δυνητικής προγνωστικής αξίας των προθεραπευτικών επιπέδων αδιπονεκτίνης στον ορό και σε δείγματα βρογχοκυψελιδικής έκπλυσης (bronchoalveolar lavage, BAL) ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα (ΜΜΚΠ) προχωρημένου σταδίου. Στον παρόν ερευνητικό έργο μελετήθηκαν προοπτικά 29 νεοδιαγνωσθέντες ασθενείς με ΜΜΚΠ σταδίου IV. Τα προθεραπευτικά επίπεδα αδιπονεκτίνης ορού και BAL μετρήθηκαν με τη χρήση ανοσοενζυμικής μεθόδου (ELISA), και, ακολούθως, συσχετίσθηκαν με δημογραφικές, κλινικές και παθολογοανατομικές παραμέτρους. Αναλυτικότερα, οι παράμετροι που αξιολογήθηκαν συμπεριελάμβαναν το φύλο, την ηλικία, το Performance Status (PS), το δείκτη μάζας σώματος (Body Mass Index, BMI), την απώλεια βάρους > 10%, καθώς και τον ιστολογικό τύπο, βαθμό διαφοροποίησης (grade) και μέγεθος του πρωτοπαθούς όγκου. Η συσχέτιση των επιπέδων αδιπονεκτίνης και των λοιπών μεταβλητών με τη συνολική επιβίωση των ασθενών αξιολογήθηκε με μονοπαραγοντική και πολυπαραγοντική ανάλυση παλινδρόμησης του Cox (univariate and multivariate Cox regression analysis).Σύμφωνα με τα αποτελέσματα της μελέτης μας, η μέση ηλικία των ασθενών ήταν 65.6 έτη (SD= 10.1 έτη), ενώ η πλειοψηφία ήταν άνδρες (24/29 περιπτώσεις, 82.8%). Ο κυρίαρχος ιστολογικός τύπος ήταν το αδενοκαρκίνωμα (18/29 περιπτώσεις, 62.1%). Η λειτουργική κατάσταση (performance status, PS) των ασθενών ήταν 0 και 1-2 σε 17/29 περιπτώσεις (58.6%) και 12/29 περιπτώσεις (41.4%), αντιστοίχως. Απώλεια βάρους μεγαλύτερη του 10% παρατηρήθηκε σε 10/29 ασθενείς (34.5%). Οι διάμεσες τιμές επιπέδων αδιπονεκτίνης σε ορό και BAL ήταν 17710 ng/ml και 911.5 ng/ml, αντιστοίχως. Δεν παρατηρήθηκαν στατιστικώς σημαντικές συσχετίσεις μεταξύ των επιπέδων αδιπονεκτίνης (τόσο στον ορό όσο και στο BAL) και των κλινικών και παθολογοανατομικών παραμέτρων που αξιολογήθηκαν. Η μονοπαραγοντική ανάλυση παλινδρόμησης του Cox έδειξε ότι τα επίπεδα αδιπονεκτίνης δεν συσχετίζονταν σε στατιστικά σημαντικό βαθμό με την επιβίωση. Ο μόνος προγνωστικός παράγοντας που αναγνωρίστηκε, τόσο στη μονοπαραγοντική όσο και στην πολυπαραγοντική ανάλυση επιβίωσης, ήταν το PS [Hazard ratio (95% Confidence Interval): 2.75 (1.17-6.46), (p=0.02)]Συμπερασματικά, τα αποτελέσματα της προοπτικής μας μελέτης απέτυχαν να αναδείξουν στατιστικά σημαντικά συσχετίσεις των επιπέδων αδιπονεκτίνης (ορού και BAL) με τη συνολική επιβίωση καθώς και με τις δημογραφικές και κλινικοπαθολογοανατομικές παραμέτρους που αξιολογήθηκαν (συμπεριλαμβανομένου του BMI και της απώλειας βάρους), σε ασθενείς με ΜΜΚΠ σταδίου IV, σε συμφωνία με τις περισσότερες προηγούμενες κλινικές παρατηρήσεις.

scholarly journals CCBE1 is a Prognostic Biomarker and Contributes to Prostate Cancer Cell Progression.

2021 ◽  
Author(s):  
Peizhang Li ◽  
Huan Xu ◽  
Ming Zhan ◽  
Yanbo Chen ◽  
Dachao Zheng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Regression Analysis ◽  
Confidence Interval ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cox Regression ◽  
Hazard Ratio ◽  
Cancer Tissue ◽  
Cox Regression Analysis ◽  
Kaplan Meier

Abstract Subject: Collagen And Calcium Binding EGF Domains 1 (CCBE1) is a coding protein which plays a significant role in extracellular matrix remodeling and migration and is involved in the development of Hennekam syndrome and lymphangiogenesis. Here, we investigate its prognostic value in prostate cancer based on TCGA database and its antioncogenic role in prostate cancer.Methods: Wilcoxon rank sum test, Pearson χ2 test, and logistic regression analysis were utilized to evaluate the correlation between CCBE1 and clinicopathological variables. Kaplan-Meier and Cox regression analysis were used to reveal the relation between CCBE1 and survival rates. The role of CCBE1 in prostate cancer was investigated using CCK-8 assay, EdU assay, and transwell experiments, respectively.Results: Here, we found that CCBE1 expression is down-regulated in prostate cancer tissue dramatically in TCGA database. Furthermore, high CCBE1 expression predicted a good prognosis in patients with prostate cancer. High expression level of CCBE1 in PRAD cohort was prominently correlated with T classification (OR =0.49 for T3&T4 vs T2, P<0.001), Gleason score (OR = 0.42 for8&9&10 vs. 6&7, P<0.001). Kaplan-Meier and Cox regression analysis showed that prostate cancer patients with high CCBE1 expression had a better progression-free interval (hazard ratio [HR]:0.50; 95% confidence interval [CI]: 0.33-0.77; P = 0.002) and overall survival (hazard ratio [HR]:0.38; 95% confidence interval [CI]: 0.15-0.92; P = 0.032). In vitro experiments indicated that overexpressed CCBE1 inhibited prostate cancer cell proliferation, migration, and invasion.Conclusion: CCBE1 plays a pivotal role in the progression of prostate cancer and up-regulated CCBE1 expression inhibits prostate cancer tumorgenicity.

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate

2020 ◽  
pp. 135245852091848
Author(s):  
Viktor von Wyl ◽  
Pascal Benkert ◽  
André Moser ◽  
Johannes Lorscheider ◽  
Bernhard Décard ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Regression Analysis ◽  
Confidence Interval ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Cox Regression ◽  
Hazard Ratio ◽  
Disability Progression ◽  
Cox Regression Analysis ◽  
Multiple Sclerosis Patients

Background: Disability progression independent of relapses (PIRA) has been described as a frequent phenomenon in relapsing-remitting multiple sclerosis (RRMS). Objective: To compare the occurrence of disability progression in relapse-free RRMS patients on interferon-beta/glatiramer acetate (IFN/GA) versus fingolimod. Methods: This study is based on data from the Swiss association for joint tasks of health insurers. Time to relapse and 12-month confirmed disability progression were compared between treatment groups using multivariable Cox regression analysis with confounder adjustment. Inverse-probability weighting was applied to correct for the bias that patients on fingolimod have a higher chance to remain relapse-free than patients on IFN/GA. Results: We included 1640 patients (64% IFN/GA, 36% fingolimod, median total follow-up time = 4–5 years). Disease-modifying treatment (DMT) groups were well balanced with regard to potential confounders. Disability progression was observed in 155 patients (8.8%) on IFN/GA and 51 (7.6%) on fingolimod, of which 44 and 23 were relapse-free during the initial DMT, respectively. Adjusted standard regression analysis on all patients indicated that those on fingolimod experience less frequently disability progression compared with IFN/GA (hazard ratio = 0.53 (95% confidence interval = 0.37–0.76)). After bias correction, this was also true for patients without relapses (hazard ratio=0.56 (95% confidence interval = 0.32–0.98). Conclusion: Our analysis indicates that fingolimod is superior to IFN/GA in preventing disability progression in both relapsing and relapse-free, young, newly diagnosed RRMS patients.

scholarly journals Triglyceride glucose-body mass index in identifying high-risk groups of pre-diabetes

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Chunyuan Jiang ◽  
Ruijuan Yang ◽  
Maobin Kuang ◽  
Meng Yu ◽  
Mingchun Zhong ◽  
...  
Keyword(s):  
Body Mass Index ◽  
High Risk ◽  
Diagnostic Criteria ◽  
Body Mass ◽  
Cox Regression ◽  
Risk Groups ◽  
World Health ◽  
Obese People ◽  
Cox Regression Analysis ◽  
Health Organization

Abstract Background Triglyceride glucose-body mass index (TyG-BMI) has been recommended as an alternative indicator of insulin resistance. However, the association between TyG-BMI and pre-diabetes remains to be elucidated. Methods More than 100,000 subjects with normal glucose at baseline received follow-up. The main outcome event of concern was pre-diabetes defined according to the diagnostic criteria recommended by the American Diabetes Association (ADA) in 2018 and the World Health Organization (WHO) in 1999. A Cox proportional hazard regression model was used to evaluate the role of TyG-BMI in identifying people at high risk of pre-diabetes. Results At a mean observation period of 3.1 years, the incidence of pre-diabetes in the cohort was 3.70 and 12.31% according to the WHO and ADA diagnostic criteria for pre-diabetes, respectively. The multivariate Cox regression analysis demonstrated that TyG-BMI was independently positively correlated with pre-diabetes, and there was a special population dependence phenomenon. Among them, non-obese people, women and people under 50 years old had a significantly higher risk of TyG-BMI-related pre-diabetes (P-interaction< 0.05). Conclusions These findings suggest that a higher TyG-BMI significantly increases an individual’s risk of pre-diabetes, and this risk is significantly higher in women, non-obese individuals, and individuals younger than 50 years of age.

scholarly journals Physical activity modifies the risk of atrial fibrillation in obese individuals: The HUNT3 study

2018 ◽  
Vol 25 (15) ◽  
pp. 1646-1652 ◽  
Author(s):  
Lars E Garnvik ◽  
Vegard Malmo ◽  
Imre Janszky ◽  
Ulrik Wisløff ◽  
Jan P Loennechen ◽  
...  
Keyword(s):  
Physical Activity ◽  
Atrial Fibrillation ◽  
Body Mass Index ◽  
Confidence Interval ◽  
Body Mass ◽  
High Body Mass Index ◽  
Overweight And Obesity ◽  
Hazard Ratio ◽  
Increased Risk

Background Atrial fibrillation is the most common heart rhythm disorder, and high body mass index is a well-established risk factor for atrial fibrillation. The objective of this study was to examine the associations of physical activity and body mass index and risk of atrial fibrillation, and the modifying role of physical activity on the association between body mass index and atrial fibrillation. Design The design was a prospective cohort study. Methods This study followed 43,602 men and women from the HUNT3 study in 2006–2008 until first atrial fibrillation diagnosis or end of follow-up in 2015. Atrial fibrillation diagnoses were collected from hospital registers and validated by medical doctors. Cox proportional hazard regression analysis was performed to assess the association between physical activity, body mass index and atrial fibrillation. Results During a mean follow-up of 8.1 years (352,770 person-years), 1459 cases of atrial fibrillation were detected (4.1 events per 1000 person-years). Increasing levels of physical activity were associated with gradually lower risk of atrial fibrillation ( p trend 0.069). Overweight and obesity were associated with an 18% (hazard ratio 1.18, 95% confidence interval 1.03–1.35) and 59% (hazard ratio 1.59, 95% confidence interval 1.37–1.84) increased risk of atrial fibrillation, respectively. High levels of physical activity attenuated some of the higher atrial fibrillation risk in obese individuals (hazard ratio 1.53, 95% confidence interval 1.03–2.28 in active and 1.96, 95% confidence interval 1.44–2.67 in inactive) compared to normal weight active individuals. Conclusion Overweight and obesity were associated with increased risk of atrial fibrillation. Physical activity offsets some, but not all, atrial fibrillation risk associated with obesity.

scholarly journals The association of dialysis adequacy, body mass index, and mortality among hemodialysis patients

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Woong-pyo Hong ◽  
Yu-Ji Lee
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Mortality Risk ◽  
Cox Regression ◽  
Target Range ◽  
Dialysis Adequacy ◽  
Cox Regression Analysis ◽  
Increased Risk ◽  
All Cause Mortality ◽  
High Bmi

Abstract Background Although hemodialysis (HD) adequacy, single-pool Kt/Vurea (spKt/V), is inversely correlated with body size, each is known to affect patient survival in the same direction. Therefore, we sought to examine the relationship between HD adequacy and mortality according to body mass index (BMI) in HD patients and explore a combination effect of BMI and HD adequacy on mortality risk. Methods We retrospectively reviewed patient data from the Korean Society of Nephrology registry, a nationwide database of medical records of HD patients, from January 2001 to June 2017. We included patients ≥18 years old who were receiving maintenance HD. Patients were categorized into three groups according to baseline BMI (< 20 (low), 20 to < 23 (normal), and ≥ 23 (high) kg/m2). Baseline spKt/V was divided into six categories. Results Among 18,242 patients on HD, the median follow-up duration was 5.2 (IQR, 1.9–8.9) years. Cox regression analysis showed that, compared to the reference (spKt/V 1.2–1.4), lower and higher baseline spKt/V were associated with greater and lower risks for all-cause mortality, respectively. However, among patients with high BMI (n = 5588), the association between higher spKt/V and lower all-cause mortality was attenuated in all adjusted models (Pinteraction < 0.001). Compared to patients with normal BMI and spKt/V within the target range (1.2–1.4), those with low BMI had a higher risk for all-cause mortality at all spKt/V levels. However, the gap in mortality risk became narrower for higher values of spKt/V. Compared to patients with normal BMI and spKt/V in the target range, those with high BMI and spKt/V < 1.2 were not at increased risk for mortality despite low dialysis adequacy. Conclusions The association between spKt/V and mortality in HD patients may be modified by BMI.

scholarly journals Does Hemoperfusion Increase Survival in Acute Paraquat Poisoning? A Retrospective Multicenter Study

Toxics ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 84
Author(s):  
Ying-Tse Yeh ◽  
Chun-Kuei Chen ◽  
Chih-Chuan Lin ◽  
Chia-Ming Chang ◽  
Kai-Ping Lan ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Retrospective Study ◽  
Confidence Interval ◽  
Cox Regression ◽  
Severity Index ◽  
Cox Regression Analysis ◽  
Medical Centers ◽  
Paraquat Poisoning ◽  
Significant Difference ◽  
Retrospective Multicenter Study

The efficacy of hemoperfusion (HP) in patients with acute paraquat poisoning (PQ) remains controversial. We conducted a multi-center retrospective study to include acute PQ-poisoned patients admitted to two tertiary medical centers between 2005 and 2015. We used the Severity Index of Paraquat Poisoning (SIPP) to stratify the severity of PQ-poisoned patients. The indication to start HP was a positive result for the semiquantitative urine PQ test and presentation to the hospital was within 24 h. Early HP was defined as the first session of HP performed within five hours of PQ ingestion. A total of 213 patients (100 HP group, 113 non-HP group) were eligible for the study. The overall 60-day mortality of poisoned patients was 75.6% (161/213). Multivariate Cox regression analysis showed no statistically significant difference in 60-day survival between HP and non-HP groups (95% confidence interval (CI): 0.84–1.63, p = 0.363). Further subgroup analysis in the HP group showed early HP (95% CI: 0.54–1.69, p = 0.880), and multiple secessions of HP (95% CI: 0.56–1.07, p = 0.124) were not significantly related to better survival. Among acute PQ-poisoned patients, this study found that HP was not associated with increased 60-day survival. Furthermore, neither early HP nor multiple secessions of HP were associated with survival.

scholarly journals Prevalence of Kidney Injury and Associations with Critical Illness and Death in Patients with COVID-19

2020 ◽  
Vol 15 (11) ◽  
pp. 1549-1556 ◽  
Author(s):  
Xizi Zheng ◽  
Hongyu Yang ◽  
Xiaolong Li ◽  
Haichao Li ◽  
Lingyi Xu ◽  
...  
Keyword(s):  
Critical Illness ◽  
Confidence Interval ◽  
Cox Regression ◽  
Kidney Injury ◽  
Hazard Ratio ◽  
Secondary Outcome ◽  
Cox Regression Analysis ◽  
Shenzhen City ◽  
Critical Patients

Background and objectivesCoronavirus disease 2019 is spreading rapidly across the world. This study aimed to assess the characteristics of kidney injury and its association with disease progression and death of patients with coronavirus disease 2019.Design, setting, participants, & measurementsThis is a retrospective study. Two representative cohorts were included. Cohort 1 involved severe and critical patients with coronavirus disease 2019 from Wuhan, China. Cohort 2 was all patients with coronavirus disease 2019 in Shenzhen city (Guangdong province, China). Any kidney injury was defined as the presence of any of the following: hematuria, proteinuria, in-hospital AKI, or prehospital AKI. AKI was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) creatinine criteria. The primary outcome was death at the end of follow-up. The secondary outcome was progression to critical illness during the study period.ResultsA total of 555 patients were enrolled; 42% of the cases (229 of 549) were detected with any kidney injury, 33% of the cases (174 of 520) were detected with proteinuria, 22% of the cases (112 of 520) were detected with hematuria, and 6% of the cases (29 of 520) were detected with AKI. Of the 29 patients with AKI, 21 cases were recognized as in-hospital AKI, and eight were recognized as prehospital AKI. Altogether, 27 (5%) patients died at the end of follow-up. The death rate was 11% (20 of 174) in patients with proteinuria, 16% (18 of 112) in patients with hematuria, and 41% (12 of 29) in the AKI settings. Multivariable Cox regression analysis showed that proteinuria (hazard ratio, 4.42; 95% confidence interval, 1.22 to 15.94), hematuria (hazard ratio, 4.71; 95% confidence interval, 1.61 to 13.81), and in-hospital AKI (hazard ratio, 6.84; 95% confidence interval, 2.42 to 19.31) were associated with death. Among the 520 patients with noncritical illness at admission, proteinuria (hazard ratio, 2.61; 95% confidence interval, 1.22 to 5.56) and hematuria (hazard ratio, 2.50; 95% confidence interval, 1.23 to 5.08) were found to be associated with progression to critical illness during the study period.ConclusionsKidney injury is common in coronavirus disease 2019, and it is associated with poor clinical outcomes.PodcastThis article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_09_18_CJN04780420.mp3

scholarly journals Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

2020 ◽  
Vol 8 (2) ◽  
pp. e001117
Author(s):  
Piotr Rutkowski ◽  
Alice Indini ◽  
Matilde De Luca ◽  
Barbara Merelli ◽  
Anna Mariuk-Jarema ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Metastatic Melanoma ◽  
Risk Reduction ◽  
Body Mass ◽  
Regression Models ◽  
Cox Regression ◽  
Checkpoint Inhibitors ◽  
Performance Status ◽  
Prognostic Role ◽  
First Line

BackgroundObesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma is controversial. We aim to investigate the prognostic role of body mass index (BMI) in patients with metastatic melanoma receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint inhibitors (ICIs) alone or their sequence.MethodsData on patients with metastatic melanoma receiving ≥1 line of systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall survival (OS) were analyzed by means of multivariable stratified Cox regression models; disease control rate (DCR) was analyzed by multivariable stratified logistic regression models. Subgroup analyzes according to the type of treatments received, and in BRAF-mutated patients were pre-planned. All multivariable models included BMI, age, gender, American Joint Committee on Cancer stage, performance status, lactate dehydrogenase and treatment sequencing strategy as covariates.ResultsBetween November 2010 and November 2018, 688 patients from three Italian and two Polish centers were enrolled. 379 (57%) patients had M1c/d disease, 273 (41%) were female and the mean BMI was 27.1 (SD=4.9). Considering first-line treatment, 446 patients (66.8%) received ICIs and 222 MAPKi. No impact of BMI on OS was detected either considering the first line of ICIs, or ICIs sequencing (HR=1.02, 95% CI: 0.99 to 1.05, p=0.202, and HR=1.02, 95% CI: 0.99 to 1.04, p=0.237, respectively). A late effect of BMI on OS was found in patients treated with MAPKi: for five units increment, a 51% of risk reduction at 18 months and a 76% of risk reduction at 30 months were observed. No significant effect of BMI on PFS and DCR was found in any of the subgroup analyzes.ConclusionIn patients with metastatic melanoma receiving ICIs, there is no impact of BMI on DCR, PFS and OS. The late prognostic effect of BMI in patients treated with MAPKi should be considered hypothesis generating and needs to be further investigated.

scholarly journals Treatment outcomes and its associated factors among breast cancer patients at Kitui Referral Hospital

2022 ◽  
Vol 10 ◽  
pp. 205031212110678
Author(s):  
Mwendwa Dickson Wambua ◽  
Amsalu Degu ◽  
Gobezie T Tegegne
Keyword(s):  
Breast Cancer ◽  
Regression Analysis ◽  
Confidence Interval ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Medical Records ◽  
Cox Regression ◽  
Breast Cancer Patients ◽  
Cox Regression Analysis ◽  
Study Setting

Objectives: Despite breast cancer treatment outcomes being relatively poor or heterogeneous among breast cancer patients, there was a paucity of data in the African settings, especially in Kenya. Hence, this study aimed to determine treatment outcomes among breast cancer patients at Kitui Referral Hospital. Methods: A hospital-based retrospective cohort study design was conducted among adult patients with breast cancer. All eligible breast cancer patients undergoing treatment from January 2015 to June 2020 in the study setting were included. Hence, a total of 116 breast cancer patients’ medical records were involved in the study. Patients’ medical records were retrospectively reviewed using a predesigned data abstraction tool. The data were entered, cleaned, and analyzed using SPSS (Statistical Package for Social Sciences) version 26 software. Descriptive analysis—such as percentage, frequency, mean, and figures—was used to present the data. Kaplan–Meier survival analysis was used to estimate the mean survival estimate across different variables. A Cox regression analysis was employed to determine factors associated with mortality. Results: The study showed that the overall survival and mortality rate was 62.9% (73) and 37.1% (43), respectively. The regression analysis showed that patients who had an advanced stage of disease had a 3.82 times risk of dying (crude hazard ratio= 3.82, 95% confidence interval = 1.5–9.8) than an early stage of the disease. Besides, patients with distant metastasis had 4.4 times more hazards of dying than (crude hazard ratio = 4.4, 95% confidence interval = 2.1–9.4) their counterparts. Conclusion: The treatment outcome of breast cancer patients was poor, and its overall mortality among breast cancer patients was higher in the study setting. In the multivariate Cox regression analysis, the tumor size was the only statistically significant predictor of mortality among breast cancer patients. Stakeholders at each stage should, therefore, prepare a relevant strategy to improve treatment outcomes.

scholarly journals Cardio-pulmonary transit-time by cardiac magnetic resonance imaging: associates to infarct severity and adverse events after reperfused STEMI

2021 ◽  
Vol 22 (Supplement_2) ◽  
Author(s):  
F Troger ◽  
M Reindl ◽  
M Pamminger ◽  
C Tiller ◽  
M Holzknecht ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Confidence Interval ◽  
Ejection Fraction ◽  
Infarct Size ◽  
Transit Time ◽  
Cox Regression ◽  
Cox Regression Analysis ◽  
Lv Ejection Fraction

Abstract Funding Acknowledgements Type of funding sources: None. Background Cardiac magnetic resonance (CMR) data on cpTT and its associates with infarct characteristics and clinical outcome after reperfused ST-elevation myocardial infarction (STEMI) are lacking so far. Purpose To investigate cardiopulmonary-transit-time (cpTT) and its value as surrogate parameter for integrative cardiac performance and its link to heart failure. Methods A total of 207 patients (179 men [87%], median age 55 [interquartile range (IQR) 49-64] with acute STEMI underwent CMR on day 3 [IQR 2-4] and 4 months (m) [IQR 4-5] after primary percutaneous coronary intervention. cpTT was taken as the time between the peaks of time-intensity curves of gadolinium contrast to pass from the right ventricle (RV) to the left ventricle (LV). Infarct size, extent of microvascular obstruction (MVO), RV and LV dimensions and function were assessed at both occasions. Results cpTT decreased significantly between baseline and 4m CMR scan (8.6 seconds [IQR 7.5-9.6] to 7.8 sec [IQR 7-8.7], respectively, p &lt; 0.0001). Patients with presence of MVO had significantly prolonged cpTT at baseline and 4m follow-up (all p &lt; 0.022). According to Cox regression analysis ("functional model") baseline cpTT (hazard ratio (HR) 1.5, 95% confidence interval (CI) 1.1–2.2; p= 0.008) remained significantly associated to the occurrence of major adverse cardiac events (MACE) after adjustment for LV ejection fraction (EF) and cardiac index. According to Cox regression analysis ("tissue model") baseline cpTT (HR 1.462, 95% CI 1.02–2.09, p= 0.039) as well as extent of MVO (HR 1.196, 95% CI 1.081–1.324, p= 0.001) remained significantly associated to MACE after adjustment for infarct size. Baseline cpTT (area under the curve [AUC]: 0.725, 95% confidence interval [CI] 0.57-0.88; p &lt; 0.009) was significantly higher for the prediction of MACE compared to LV ejection fraction (AUC: 0.686, 95% CI 0.51-0.87; p = 0.031. AUC difference: 0.039, p &lt; 0.03). In Kaplan-Meier analysis, cpTT ≥9 sec was associated with clinical adverse cardiovascular events (p = 0.008). Conclusion Following reperfused STEMI, cpTT predicts prognosis independently of infarct size and systolic function. Moreover, cpTT provides significantly higher prognostic implication in comparison with LV ejection fraction.

Sign in / Sign up

Export Citation Format

Share Document